DNA
Ginkgo Bioworks Holdings, Inc.
There isn't enough reported data to score DNA yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
DNA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
DNA's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
DNA PE Valuation
DNA has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
DNA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect DNA's losses to grow, with revenue declining.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
DNA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.19 | +$1.90 |
| Q2 2026 | -$5.00 | +$0.72 |
| Q1 2026 | -$5.35 | +$3.67 |
| Q4 2025 | -$5.64 | +$4.90 |
| Q3 2025 | -$6.09 | +$6.59 |
| Q2 2025 | -$5.72 | +$12.28 |
| Q1 2025 | -$9.02 | +$8.18 |
| Q4 2024 | -$10.54 | +$7.86 |
DNA is still losing money, but far less than before: $4.19 per share over the past year, against $96.00 at its worst in late 2022.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over DNA on earnings quality, reporting a profit while its opponent remains loss making.
DNA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $27.7M | -29% |
| Q2 2026 | $20.2M | -59% |
| Q1 2026 | $19.5M | -60% |
| Q4 2025 | $33.4M | -24% |
| Q3 2025 | $38.8M | -56% |
| Q2 2025 | $49.6M | -12% |
| Q1 2025 | $48.3M | +27% |
| Q4 2024 | $43.8M | +26% |
DNA's revenue has slid since its 2022 peak: $28M last quarter, down 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -157% | +74 points |
| Q2 2026 | -290% | -158 points |
| Q1 2026 | -367% | -182 points |
| Q4 2025 | -212% | +24 points |
| Q3 2025 | -232% | -170 points |
| Q2 2025 | -132% | +265 points |
| Q1 2025 | -184% | +285 points |
| Q4 2024 | -236% | +276 points |
DNA's operating margin was −157% last quarter, up 74 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over DNA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over DNA on profitability, with a higher operating margin.
DNA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$30.3M | +$1.3M |
| Q2 2026 | -$46.9M | -$6.6M |
| Q1 2026 | -$48.6M | +$10.5M |
| Q4 2025 | -$47.7M | +$8.5M |
| Q3 2025 | -$31.6M | +$87M |
| Q2 2025 | -$40.3M | +$71.1M |
| Q1 2025 | -$59.1M | +$36.8M |
| Q4 2024 | -$56.1M | +$5.1M |
DNA has burned cash in almost every quarter: −$174M over the past year, against −$187M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over DNA on cash generation, producing positive trailing cash flow while its opponent burns cash.
DNA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3% | +1.9M shares |
| 1 year | +15% | +8.3M shares |
| 3 years | +31% | +15.2M shares |
| 5 years | +99% | +31.8M shares |
DNA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q4 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
DNA Net Leverage
DNA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
DNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.4 | Neutral |
| Stochastic | 37.8 | Neutral |
DNA's weekly RSI is 53 (neutral) and its Stochastic is 38 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
DNA PE vs Healthcare Sector
DNA has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
DNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.1 | 8% below |
| 20 week MA | $9.13 | 12% above |
| 50 week MA | $8.69 | 18% above |
| 100 week MA | $9.47 | 8% above |
| 200 week MA | $27.5 | 63% below |
DNA's trend is mixed: it's above three of its five weekly moving averages, and 63% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over DNA on trend strength, trading above more of its moving averages.
DNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $414.8 | $426.8 | +2.9% |
| 2022 | $426.8 | $66.4 | -84% |
| 2023 | $66.4 | $67.6 | +1.8% |
| 2024 | $67.6 | $9.66 | -86% |
| 2025 | $9.66 | $8.40 | -13% |
| 2026 YTD | $8.40 | $10.2 | +22% |
DNA has finished lower in three of the last five years. It's up 22% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over DNA on returns for 2026, with the stronger performance.